Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
CAR-T therapy, a game-changer in lupus, is showing a more complicated picture in rheumatoid arthritis (RA). In the phase I portion of the COMPARE trial, only 3 of 6 heavily pretreated RA patients achieved low disease activity after a single CAR-T infusion, while one responder later relapsed. Researchers say RA's biological heterogeneity — not the therapy itself — may be to blame.
CAR-T therapy has been making waves in autoimmune diseases like lupus, but a new trial suggests rheumatoid arthritis (RA) may be a tougher nut to crack. In the phase I portion of the COMPARE trial, presented at the American College of Rheumatology annual meeting, six patients with heavily pretreated RA received a single CAR-T cell infusion. Three achieved low disease activity within 6 months — but three didn't, and one who initially responded later relapsed.
Researchers attribute the mixed results to RA's inherent heterogeneity. Unlike lupus, where B cells are a dominant driver, B cells play a more variable role in RA — meaning the "immune reset" that CAR-T therapy delivers won't work equally well for everyone. The patient who relapsed showed notably poor CAR-T cell expansion post-infusion and early B-cell reconstitution with persistent autoreactivity, offering clues about what predicts failure.
Key Takeaways:
Why it matters: CAR-T therapy remains a realistic option for refractory RA, but patient selection will be critical. Understanding who responds — and why — could unlock a powerful new tool for one of the most treatment-resistant autoimmune conditions.
